FY2028 EPS Estimate for Moderna Cut by Analyst

Moderna, Inc. (NASDAQ:MRNA) – Equities researchers at Brookline Capital Markets reduced their FY2028 earnings per share estimates for shares of Moderna in a note issued to investors on Thursday, October 22nd. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($0.54) per share for the year, down from their previous forecast of $0.62. Brookline Capital Markets has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($6.11) per share.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same period last year, the business posted ($2.13) earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Bradesco Corretora upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. The Goldman Sachs Group boosted their price objective on Moderna from $120.00 to $137.00 and gave the stock a “neutral” rating in a research report on Thursday, October 15th. Citigroup restated a “sell” rating on shares of Moderna in a research note on Friday. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Moderna in a report on Friday, September 25th. Six investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $107.10.

Moderna Trading Down 0.6%

Shares of Moderna stock opened at $198.85 on Tuesday. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna has a 12-month low of $22.28 and a 12-month high of $254.48. The firm has a market capitalization of $79.39 billion, a price-to-earnings ratio of -24.89 and a beta of 1.09. The firm’s 50 day simple moving average is $173.86 and its two-hundred day simple moving average is $82.87.

Insider Activity at Moderna

In other news, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the sale, the president owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. The trade was a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock worth $33,875,904 in the last quarter. 10.80% of the stock is owned by company insiders.

Institutional Trading of Moderna

A number of hedge funds have recently added to or reduced their stakes in MRNA. BlackRock Inc. bought a new stake in Moderna during the 2nd quarter valued at $2,142,877,000. Theleme Partners LLP bought a new stake in shares of Moderna during the second quarter worth about $564,272,000. Wellington Management Group LLP raised its holdings in shares of Moderna by 4.4% in the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after acquiring an additional 103,977 shares during the last quarter. Merck & Co. Inc. acquired a new stake in shares of Moderna in the 2nd quarter worth about $161,642,545. Finally, Bamco Inc. NY bought a new position in Moderna in the 2nd quarter valued at about $139,317,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their individualized mRNA melanoma vaccine, intismeran, combined with KEYTRUDA, reduced the risk of recurrence or death by 42% versus KEYTRUDA alone. The trial also showed a 38% reduction in distant metastasis or death, and the results were accepted for publication in the New England Journal of Medicine. These findings support the program’s potential commercial value. Moderna Phase 3 melanoma vaccine results
• Neutral Sentiment: The vaccine’s Phase 3 success may eventually provide a significant new revenue stream for Moderna, which shares development costs and profits with Merck. However, the therapy has not yet generated sales, regulatory filings and launch timing remain uncertain, and manufacturing personalized doses at scale is untested. Moderna company information
• Negative Sentiment: Investors had anticipated results closer to the approximately 49% recurrence reduction seen in an earlier Phase 2b study. The Phase 3 benefit came in at the lower end of expectations, contributing to a sharp recent pullback despite the trial meeting its primary goal. Moderna’s rally may therefore have lost momentum as investors reassess whether the stock’s valuation already reflects much of the vaccine’s potential. Moderna cancer vaccine selloff
• Negative Sentiment: William Blair downgraded MRNA from “outperform” to “market perform,” signaling reduced expectations for further near-term upside. Separately, Brookline Capital Markets lowered its FY2028 EPS estimate from $0.62 to a loss of $0.54 per share, reinforcing concerns about the company’s path to profitability.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.